{"organizations": [], "uuid": "3de90a72c0b9426d4c8dd544985a537c5881c983", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-eisai-merck-receive-breakthrough-t/brief-eisai-merck-receive-breakthrough-therapy-designation-from-fda-for-lenvima-keytruda-idUSASB0C0B1", "country": "US", "domain_rank": 408, "title": "BRIEF-Eisai, Merck Receive Breakthrough Therapy Designation From FDA For Lenvima, Keytruda", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-09T14:02:00.000+02:00", "replies_count": 0, "uuid": "3de90a72c0b9426d4c8dd544985a537c5881c983"}, "author": "", "url": "https://www.reuters.com/article/brief-eisai-merck-receive-breakthrough-t/brief-eisai-merck-receive-breakthrough-therapy-designation-from-fda-for-lenvima-keytruda-idUSASB0C0B1", "ord_in_thread": 0, "title": "BRIEF-Eisai, Merck Receive Breakthrough Therapy Designation From FDA For Lenvima, Keytruda", "locations": [], "entities": {"persons": [{"name": "keytruda", "sentiment": "negative"}, {"name": "lenvima", "sentiment": "negative"}, {"name": "merck", "sentiment": "none"}], "locations": [], "organizations": [{"name": "fda", "sentiment": "negative"}, {"name": "merck", "sentiment": "negative"}, {"name": "keytruda reuters staff", "sentiment": "none"}, {"name": "eisai", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "eisai co ltd", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": " 03 PM / Updated 11 minutes ago BRIEF-Eisai, Merck Receive Breakthrough Therapy Designation From FDA For Lenvima, Keytruda Reuters Staff 1 Min Read \nJan 9 (Reuters) - Eisai Co Ltd: \n* EISAI AND MERCK RECEIVE BREAKTHROUGH THERAPY DESIGNATION FROM FDA FOR LENVIMA速 (LENVATINIB MESYLATE) AND KEYTRUDA速 (PEMBROLIZUMAB) AS COMBINATION THERAPY FOR ADVANCED AND/OR METASTATIC RENAL CELL CARCINOMA \n* EISAI AND MERCK RECEIVE BREAKTHROUGH THERAPY DESIGNATION FROM FDA FOR LENVIMA速 (LENVATINIB MESYLATE) AND KEYTRUDA速 (PEMBROLIZUMAB) AS COMBINATION THERAPY FOR ADVANCED AND/OR METASTATIC RENAL CELL CARCINOMA Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-01-09T14:02:00.000+02:00", "crawled": "2018-01-09T14:20:08.005+02:00", "highlightTitle": ""}